Safety and Pharmacokinetics of CD101 IV, a Novel Echinocandin, in Healthy Adults

CD101 IV is a novel echinocandin with distinctive pharmacokinetic properties that is being developed as a once-weekly treatment for candidemia and invasive candidiasis. CD101 has potent in vitro activity and in vivo efficacy against a broad range of Candida and Aspergillus species. The primary objec...

Descripción completa

Detalles Bibliográficos
Autores principales: Sandison, Taylor, Ong, Voon, Lee, Jonathan, Thye, Dirk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2017
Materias:
Clinical Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5278714/
https://www.ncbi.nlm.nih.gov/pubmed/27919901
http://dx.doi.org/10.1128/AAC.01627-16

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5278714/
https://www.ncbi.nlm.nih.gov/pubmed/27919901
http://dx.doi.org/10.1128/AAC.01627-16

Ejemplares similares